Join Us

We are always looking for talented and self-motivated graduate students and post-doc fellows interested in Bioinformatics/Computational Biology, Statistic Genetics, Functional Genomics, and their application to precision medicine including precision prevention, diagnosis, classification and treatment.

If you are interested in a position in our lab, please send your CV/resume and a brief description of your research interests to Dr. Xiaoling Zhang (zhangxl@bu.edu)

Congratulations

Congratulations to Habbiburr Rehman who has been selected as one of the two FHS-BAP pilot grant awardee. This $25,000 award will support a project entitled Identification of significant blood protein markers for the characterization of Alzheimer’s disease status and its progression in the Framingham Heart Study.

Open Position

We are looking for talented and self-motivated graduate students and post-doc fellows interested in Bioinformatics/Computational Biology, Statistic Genetics, Functional Genomics, and their application to precision medicine including precision prevention, diagnosis, classification and treatment.

If you are interested in a position in our lab, please send your CV/resume and a brief description of your research interests to Dr. Xiaoling Zhang (zhangxl@bu.edu)

Recent Notice of Award

The role of N6-methyladenosine modified RNA in Alzheimer's disease

12/2022-11/2027 R01AG080810 (Wolozin/Zhang), Total Cost: $3,955,189

Transposable elements (TE) as genomic burdens contributing to aging and neurodegeneration

9/2022-5/2027 R01AG078930-01 (Lau), Total cost: $3,600,489

Identification and characterization of the CD31-ApoE-mCRP pathway for Alzheimer's disease in humans

7/2023-6/2028 R01AG075832-01A1 (Qiu/Stein/Andrew), Total Cost: $4,080,624

Media Mentions about our research

NIH/NIA Research Highlights: Midlife cholesterol and blood sugar levels may be risk factors for Alzheimer’s disease (Zhang X, et al. Alzheimer’s & Dementia. 2022; PMID: 35319157)

           These activities relate to NIA’s AD+ADRD Research Implementation Milestone 1.I, “Test early mechanistic pathways of multiple etiologies that may account for AD/ADRD health disparities and scientifically move forward potential opportunities for precision medicine.”

Learn more about other media reports:

NMN.com4/5/2022
Fatherly 3/31/2022
Medical News Today 3/29/2022
Medpage Today 3/25/2022
News Medical 3/23/2022